Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:NTRB

Nutriband Q2 2026 Earnings Results & Report

Nutriband logo
$6.65 +0.60 (+9.92%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$6.73 +0.08 (+1.14%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nutriband missed analyst expectations on both earnings and revenue in its Q2 2026 results, released September 9, 2025. The company reported EPS of -$2.12 versus the -$0.17 consensus estimate, while revenue of $0.62 million fell short of the $0.71 million estimate by $0.09 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

Nutriband EPS Results

Actual EPS
-$2.12
Consensus EPS
-$0.17
Beat/Miss
Missed by -$1.95
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Nutriband Revenue Results

Actual Revenue
$0.62 million
Expected Revenue
$0.71 million
Beat/Miss
Missed by -$85.00 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Nutriband's next earnings date is estimated for Monday, December 7, 2026, based on past reporting schedules.

Conference Call Resources

Nutriband Q2 2026 Earnings FAQ

Nutriband (NASDAQ:NTRB) reported earnings of -$2.12 per share for Q2 2026, missing the consensus estimate of -$0.17. The report was announced on Tuesday, September 9, 2025.

Nutriband reported revenue of $0.62 million for Q2 2026, against a consensus estimate of $0.71 million.

Nutriband's next earnings date is estimated for Monday, December 7, 2026. MarketBeat tracks confirmed and estimated earnings dates for Nutriband on the company's earnings history page.

Nutriband Earnings Headlines

Nutriband Seeks New Patent Protection For AVERSA Transdermal Technology
October 8 at 7:58 PM  |  rttnews.comhttps://www.rttnews.com/3697543/nutriband-seeks-new-patent-protection-for-aversa-transdermal-technology.aspx
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
October 8 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377135/0/en/nutriband-files-new-patent-application-to-strengthen-intellectual-property-protection-of-its-transdermal-abuse-deterrent-technology.html
Elon just declared war on your phone
SpaceX reportedly agreed to pay 8 billion dollars for a major slice of U.S. wireless spectrum, and shares of AT&T, Verizon, and T-Mobile dropped within hours of the news. Elon Musk called the deal the last critical piece for complete phone coverage in America, fueling speculation about a future device that could challenge the iPhone.tc pixel
October 10 at 1:00 AM  |  Stansberry Research (Ad)
Nutriband Inc.: Nutriband Marks Five Years on Nasdaq - CEO Letter to Shareholders
October 2, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69738932-nutriband-inc-nutriband-marks-five-years-on-nasdaq-ceo-letter-to-shareholders-399.htm
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373388/0/en/nutriband-marks-five-years-on-nasdaq-ceo-letter-to-shareholders.html
Financial Review: Evolus (NASDAQ:EOLS) vs. Nutriband (NASDAQ:NTRB)
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068051
See More Nutriband Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email.

About Nutriband

Nutriband (NASDAQ:NTRB) (NASDAQ:NTRB) develops and manufactures transdermal patches and other wearable drug-delivery products for pharmaceutical, over-the-counter, consumer, and wellness markets. The company’s capabilities include product development, formulation, manufacturing, packaging, and private-label services for customers seeking patch-based delivery systems.

Nutriband’s portfolio includes consumer and wellness patches, as well as prescription-focused transdermal technologies. Its AVERSA platform is designed to incorporate abuse-deterrent features into transdermal products, with the goal of helping reduce the risk of drug extraction, misuse, or abuse. The company has also pursued applications for controlled-substance delivery, including an abuse-deterrent fentanyl patch in development.

The company serves customers in pharmaceutical, healthcare, and consumer-product markets and operates from the United States. Nutriband became publicly traded on the Nasdaq under the symbol NTRB in 2022. Its business combines contract and private-label manufacturing with the development of proprietary transdermal technologies and branded patch products.

View Nutriband Profile
Earnings Tools